{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:15:23Z","timestamp":1761920123453,"version":"3.40.5"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jns.2016.03.025","type":"journal-article","created":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T18:11:20Z","timestamp":1458151880000},"page":"145-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis"],"prefix":"10.1016","volume":"364","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-6267","authenticated-orcid":false,"given":"Luca","family":"Prosperini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvia","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.jns.2016.03.025_bb0005","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.0b013e3181dbb51c","article-title":"Freedom from disease activity in multiple sclerosis","volume":"74","author":"Havrdova","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.03.025_bb0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2016.03.025_bb0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2016.03.025_bb0020","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1212\/WNL.0000000000002105","article-title":"Long-term assessment of no evidence of disease activity in relapsing-remitting MS","volume":"85","author":"De Stefano","year":"2015","journal-title":"Neurology"},{"year":"2015","author":"Havrdova","key":"10.1016\/j.jns.2016.03.025_bb0025"},{"key":"10.1016\/j.jns.2016.03.025_bb0030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jns.2012.08.027","article-title":"Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis","volume":"323","author":"Prosperini","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2016.03.025_bb0035","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2016.03.025_bb0040","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O'Connor","year":"2011","journal-title":"Neurology"},{"issue":"Suppl. 3","key":"10.1016\/j.jns.2016.03.025_bb0045","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10072-010-0344-z","article-title":"Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study","volume":"31","author":"Sangalli","year":"2011","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2016.03.025_bb0050","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study","volume":"8","author":"Havrdova","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2016.03.025_bb0055","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/2013.jamaneurol.211","article-title":"Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic","volume":"70","author":"Altay","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2016.03.025_bb0060","doi-asserted-by":"crossref","DOI":"10.1177\/1352458515616701","article-title":"Inclusion of brain volume loss in a revised measure of \u2018no evidence of disease activity\u2019 (NEDA-4) in relapsing-remitting multiple sclerosis","author":"Kappos","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2016.03.025_bb0065","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/WCO.0000000000000095","article-title":"Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink?","volume":"27","author":"Filippi","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jns.2016.03.025_bb0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/ern.12.5","article-title":"Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis","volume":"12","author":"Costelloe","year":"2012","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jns.2016.03.025_bb0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40263-015-0226-2","article-title":"Infection risk in patients on multiple sclerosis therapeutics","volume":"29","author":"Williamson","year":"2015","journal-title":"CNS Drugs"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16301575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16301575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T04:52:24Z","timestamp":1536900744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X16301575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":15,"alternative-id":["S0022510X16301575"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2016.03.025","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2016.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}